Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
about
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of LiteratureEfficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German CentersCytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer.No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.Is in vitro-acquired resistance to enzalutamide a useful model?Sequential therapies in castration-resistant prostate cancer.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.
P2860
Q26750735-3DA50956-0021-4416-9164-98A4B9C8CF7CQ37726362-836B1CB7-0017-4EEB-8098-FB31426DCCE3Q38232184-87E3AEBD-1428-4F63-9CD6-5C3620293AFDQ38530028-EC9C2453-06D0-4D03-A772-A1578D76D734Q38588658-86AC712A-0992-4587-97B5-F751369E8459Q38696205-039558D8-ADAF-4602-B971-AE4A13165DC9Q38730792-B58C09F5-EEAE-49C1-893C-6B697AAB5641Q40820466-589D14BA-88AF-4938-8117-DDFDF223D861Q41332423-5778EBEF-AAD4-4B10-96B5-DCCA29E8FD35Q41721844-5FFF24BC-A14F-4113-AC3F-EF5ED29E45D3Q48110667-58C3AE62-7748-44C3-8C69-7EC6312D7FCFQ48658920-4CF8C8F1-2F0F-4502-AC18-C01B78184C8BQ49056452-1EEFFE95-4FE6-4AB8-B86D-12C34EB6000FQ51465026-9A7032E2-9744-4892-AD2E-31099B5DAFCEQ53822455-D697EC17-A578-453E-B697-9BAF3DD9B11CQ55519124-FBDA57ED-EEAB-4411-90A9-E79B3D06D207
P2860
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Potential value of Gleason sco ...... ion-resistant prostate cancer.
@en
Potential value of Gleason sco ...... ion-resistant prostate cancer.
@nl
type
label
Potential value of Gleason sco ...... ion-resistant prostate cancer.
@en
Potential value of Gleason sco ...... ion-resistant prostate cancer.
@nl
prefLabel
Potential value of Gleason sco ...... ion-resistant prostate cancer.
@en
Potential value of Gleason sco ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Potential value of Gleason sco ...... tion-resistant prostate cancer
@en
P2093
Antonella Virtuoso
Davide Bosso
Giovannella Palmieri
Giuseppe Di Lorenzo
Gregory R Pond
Guru Sonpavde
Livio Puglia
Luca Vaccaro
Michela Izzo
Piera Federico
P2860
P304
P356
10.2217/FON.13.39
P407
P577
2013-06-01T00:00:00Z